$10.14
6.62% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US67080M1036
Symbol
NRIX
Sector
Industry

Nurix Therapeutics Inc Stock price

$10.14
-0.41 3.89% 1M
-12.50 55.21% 6M
-8.70 46.18% YTD
-6.05 37.37% 1Y
+0.16 1.60% 3Y
-8.87 46.66% 5Y
-8.87 46.66% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.63 6.62%
ISIN
US67080M1036
Symbol
NRIX
Sector
Industry

Key metrics

Market capitalization $773.03m
Enterprise Value $249.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.43
P/S ratio (TTM) P/S ratio 13.70
P/B ratio (TTM) P/B ratio 1.61
Revenue growth (TTM) Revenue growth -30.25%
Revenue (TTM) Revenue $56.42m
EBIT (operating result TTM) EBIT $-230.67m
Free Cash Flow (TTM) Free Cash Flow $-201.59m
Cash position $549.68m
EPS (TTM) EPS $-2.81
P/E forward negative
P/S forward 12.24
EV/Sales forward 3.96
Short interest 21.10%
Show more

Is Nurix Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Nurix Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Nurix Therapeutics Inc forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Nurix Therapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Nurix Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Feb '25
+/-
%
56 56
-
100%
- Direct Costs 17 17
-
30%
40 40
-
70%
- Selling and Administrative Expenses 22 22
-
39%
- Research and Development Expense 232 232
-
411%
-214 -214
-
-379%
- Depreciation and Amortization 17 17
-
30%
EBIT (Operating Income) EBIT -231 -231
-
-409%
Net Profit -208 -208
-
-369%

In millions USD.

Don't miss a Thing! We will send you all news about Nurix Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nurix Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
SAN FRANCISCO, May 16, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on May 1...
Neutral
GlobeNewsWire
6 days ago
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in a fireside ch...
Neutral
GlobeNewsWire
7 days ago
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company's ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic ...
More Nurix Therapeutics Inc News

Company Profile

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Head office United States
CEO Arthur Sands
Employees 286
Founded 2009
Website www.nurixtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today